Medical/Pharmaceuticals

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's 85th Scientific Sessions

* In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly treatment in patients with type 2 diabetes mellitus (T2DM), with significant HbA1c reductions alongside comprehensive benefits for body weig...

2025-06-21 19:06 3829

Everest Medicines Announces Successful Release of First Clinical Batch of Tumor-Associated Antigen Vaccine EVM14 at Jiashan Manufacturing Site

SHANGHAI, June 20, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced the successful release of the first ...

2025-06-20 20:09 3133

Gene Solutions Strengthens China Footprint with Strategic Partnerships in Precision Oncology

BEIJING, June 20, 2025 /PRNewswire/ -- Gene Solutions  announces the signing of two strategic Memoranda of Understanding (MOUs) withZaoDx and Xiong'an MagicBiotech Co., Ltd . These partnerships mark a...

2025-06-20 16:30 3760

The Department of Health - Abu Dhabi and Abbot Unite to Manufacture Pharmaceuticals Locally in Abu Dhabi

Reinforcing Abu Dhabi's position as a global life science hub ABU DHABI, UAE, June 20, 2025 /PRNewswire/ -- During BIO International Convention in Boston USA, theDepartment of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, and Abbott,...

2025-06-20 16:00 2562

Cochlear celebrates 30 Years in China and the launch of the world's first and only smart hearing implant system

* The new Cochlear™ Nucleus® Nexa™ System is the first and only hearing implant featuring internal memory and upgradeable firmware.1+ * This year marks the 30-year anniversary since the first adult cochlear implant surgery in mainland China which took place in 1995. * Nearly 10 million peopl...

2025-06-20 12:02 3682

Ottai Unveils Revolutionary AI-Powered Biosensor Set to Transform Chronic Disease Care

Groundbreaking Technology Empowers Patients to Take Control of Their Health HONG KONG, June 20, 2025 /PRNewswire/ -- Ottai, an Oxford-originated pioneer in AI digital health innovation, today announced the launch of its next-generation AI-powered wearable designed to revolutionize chronic diseas...

2025-06-20 12:00 2177

Dizal Completes Enrollment for its Phase III Pivotal Study of Sunvozertinib vs. Platinum Doublet in Treatment Naïve NSCLC Patients with EGFR Exon20 Insertional Mutations

SHANGHAI, June 19, 2025 /PRNewswire/ -- Dizal announced the completion of patient enrollment for its WU-KONG28 clinical trial: a multinational, randomized phase III study evaluating the efficacy and safety of sunvozertinib versus platinum-based doublet chemotherapies as a first-line treatment for...

2025-06-19 18:08 2466

The Department of Health - Abu Dhabi and Sanofi Forge Strategic Alliance to Accelerate the Development of New Global Vaccines in Abu Dhabi

On the sidelines of a high-level US visit focused on healthcare innovation ABU DHABI, UAE, June 19, 2025 /PRNewswire/ -- The Department of Health – Abu Dhabi  (DoH), the regulator of the healthcare sector inAbu Dhabi, has signed a Memorandum of Understanding (MoU) with...

2025-06-19 16:00 2858

111, Inc. Announces First Quarter 2025 Unaudited Financial Results

* Maintained Quarterly Operational Profitability * Operating Expenses as a Percentage of Revenues Decreased 30 Basis Points YoY * Maintained Quarterly Positive Operating Cash Flow SHANGHAI, June 19, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled h...

2025-06-19 15:03 4799

Immuno Cure and PharmaJet Announce Collaboration to Advance a Novel HIV Therapeutic DNA Vaccine Using Needle-Free Technology in Humans

HONG KONG, June 19, 2025 /PRNewswire/ -- Immuno Cure BioTech ("Immuno Cure"), a clinical-stage biotechnology group based in Hong Kong Science Park, is pleased to announce its upcoming collaboration with PharmaJet® to evaluate the safety and immunogenicity of HIV therapeutic DNA vaccine, ICVAX, de...

2025-06-19 14:11 2582

Novo Holdings Reports Strong Momentum in Asia Across Healthcare and Planetary Health in 2024

Landmark investments, portfolio progress, and expanded presence position Novo Holdings for long-term growth and impact in Asia SINGAPORE, June 19, 2025 /PRNewswire/ -- Novo Holdings today released its Asia Investments Year in Review 2024, highlighting a year of strategic growth and purpose-driven...

2025-06-19 09:00 2729

MALAYSIA HIGHLIGHTS MEDICAL AND TOURISM SYNERGY AT THE MALAYSIA HEALTHCARE EXPO MAKASSAR 2025

Over 15 Malaysian hospitals and Tourism Selangor spotlight world-class care and vibrant recovery tourism for Indonesian patients, led by the Malaysia Healthcare Travel Council KUALA LUMPUR, Malaysia, June 19, 2025 /PRNewswire/ -- The Malaysia Healthcare Travel Council (MHTC), in collaboration w...

2025-06-19 08:50 3936

Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refractory Multiple Myeloma

SHANGHAI, June 18, 2025 /PRNewswire/ -- Simcere Zaiming, an innovative oncology-focused subsidiary of Simcere Pharmaceutical Group (2096.HK) today announced the first US patient has started treatment in the ongoing Phase 1 trial (SIM0500-101,NCT06375044

2025-06-19 08:37 2927

LOTTE BIOLOGICS Signs Antibody Manufacturing Contract with Ottimo Pharma

* Expanding track record by signing contracts with various global companies across Asia and Europe SEOUL, South Korea, June 18, 2025 /PRNewswire/ -- LOTTE BIOLOGICS announced on June 19, 2025 that it has signed a contract manufacturing agreement for antibody therapeutics with Ottimo Pharma, a ...

2025-06-19 07:00 4287

MedHub-AI Receives PMDA Approval in Japan for AutocathFFR®

TEL AVIV, Israel, June 18, 2025 /PRNewswire/ -- MedHub-AI , a global leader in AI-powered cardiovascular diagnostics, announced today that the Pharmaceuticals and Medical Devices Agency (PMDA) inJapan has approved AutocathFFR®, the company's non-invasive, AI-driven sof...

2025-06-19 07:00 3381

Frost & Sullivan Names Dassault Systèmes as Recipient of Its 2025 Global Transformational Innovation Leadership Award for Excellence in Smart Manufacturing Life Sciences Solutions

Recognized for its leadership in driving digital transformation and sustainable innovation through virtual twin technology in the life sciences manufacturing sector. SAN ANTONIO, June 19, 2025 /PRNewswire/ -- Frost & Sullivan is pleased to announce thatDassault Systèmes has been awarded the 2025...

2025-06-19 00:15 2649

Backed by $2 Million, Droplet IV is Set to Launch its Revolutionary Automatic IV-Line Flushing Device in EU & US in 2026

COPENHAGEN, Denmark, June 18, 2025 /PRNewswire/ -- Droplet IV today announced the successful completion of a $2 million funding round to enable launch of its first automatic IV-line flushing device in the EU and US markets. The device addresses a critical need among nurses, who currently spend si...

2025-06-18 23:35 2535

Medison Expands Global Leadership Team with Chief Business Officer and Chief Legal & Compliance Officer

Strategic appointments reflect Medison's continued investment in global scale and operational excellence PETACH TIKVA, Israel, June 18, 2025 /PRNewswire/ -- Medison , the creator of a first-of-its-kind unified global commercialization platform that accelerates th...

2025-06-18 22:41 2103

Medison Expands Global Leadership Team with Chief Business Officer and Chief Legal & Compliance Officer

Strategic appointments reflect Medison's continued investment in global scale and operational excellence PETACH TIKVA, Israel, June 18, 2025 /PRNewswire/ -- Medison , the creator of a first-of-its-kind unified global commercialization platform that accelerates the...

2025-06-18 22:36 1884

Paradigm Therapeutics, Inc. Announces an Additional Investment by Eshelman Ventures, LLC to Expedite Global Development and Global Registration of SD-101, A Topical Therapy for Treatment Across the Entire Skin Surface of All Subtypes of Epidermolysis Bullosa (EB)

First Topical Therapy Developed to Treat the Wounds and Lesions on the Entire Skin Surface Across All EB Subtypes Funding to be Used to Accelerate Activities Associated with Increasing Manufacturing Development of SD-101 and Commercial Launch of the SD-101 Program Globally. MT PLEASANT, S.C.,...

2025-06-18 22:00 2323
1 ... 82838485868788 ... 644